SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

Dysmenorrhea Clinical Trial

Official title:

A Multicenter, Double-blind, Randomized, Placebo-controlled Comparative Study to Investigate the Optimal Dose of Drospirenone for Dysmenorrhea With SH T04740A [Drospirenone 1 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)], SH T 04740E [Drospirenone 2 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] and SH T00186D [Drospirenone 3 mg/ Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] Administered Orally for 16 Weeks (4 Cycles), and to Confirm the Efficacy of SH T00186D for Dysmenorrhea.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00511797
• Other study ID #: 91615
• Secondary ID: 310283
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: August 3, 2007
• Last updated: December 25, 2013
• Start date: July 2007
• Est. completion date: January 2009

Study information

• Verified date: December 2013
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate efficacy of drospirenone for dysmenorrhea.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 249
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 20 years or older at obtaining informed consent

• Patients having the normal menstrual cycle (28+/-3 days) in the latest two menses before the final enrollment

• Patients having a total dysmenorrhea score of at least 3 points in two menstrual cycles before the final enrollment

Exclusion Criteria:

• Patients with ovarian chocolate cysts and symptomatic uterine fibroids (as defined in greater detail in the study protocol)

• Patients with estrogen-dependent tumors (e.g. breast cancer, cancer of the uterine body or breast fibrocystic, etc.), and patients with cervical cancer or suspected cervical cancer (e.g. class III or greater in the cervical smear or endometrial smear examination.)

• Patients with undiagnosed abnormal vaginal bleeding

• Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease(including transient ischemic attack, etc.), or coronary artery disease(e.g. myocardial infarction and angina pectoris, etc.), or a history of those diseases

• Patients aged 35 years or older who smoke at least 15 cigarettes per day

• Patients with migraine accompanied by prodrome (e.g. scintillating scotoma or star-shaped scintillation)

• Patients with pulmonary hypertension or valvular heart disease complicated by atrial fibrillation, and patients with a history of subacute bacterial endocarditis

• Patients who are regularly taking nutritional products that contain St. John's Wort

• Patients who underwent surgical treatment for endometriosis by laparotomy, or laparoscopy within 2 months prior to screening

• Patients who need to use analgesics regularly for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dysmenorrhea

Intervention

Drug:
• SH T04740B
Drospirenone 1mg/EE 20µg (ß-CDC)
• SH T00186DF
Drospirenone 3 mg/EE 20µg (ß-CDC)
• SH T04740F
Drospirenone 2 mg/EE 20µg (ß-CDC)
• Placebo
Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Momoeda M, et al. Treatment of Functional and Organic Dysmenorrhea - Investigation of the Efficacy and Safety of Drospirenone/Ethinylestradiol Combination Tablet (YAZ). Sanka to Fujinka (Obstetrics and Gynecology), 2010: 77 (8) 977-88 (in Japanese)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Total Dysmenorrheal Score at Final Evaluation	Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)	Baseline and up to 4 Cycles (28 days per cycle)	No
Secondary	Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4	Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.	Baseline and up to 4 Cycles (28 days per cycle)	No
Secondary	Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4	Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).	Cycle 4 (28 days per cycle)	No
Secondary	Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4	Severity of low back pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).	Cycle 4 (28 days per cycle)	No
Secondary	Number of Participants With Severity of Headache During Menstruation at Cycle 4	Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).	Cycle 4 (28 days per cycle)	No
Secondary	Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4	Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).	Cycle 4 (28 days per cycle)	No
Secondary	Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4	Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.	Cycle 4 (28 days per cycle)	No
Secondary	Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4	VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).	From baseline up to Cycle 4 (28 days per cycle)	No
Secondary	Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4	VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).	Cycle 4 (28 days per cycle)	No
Secondary	Change From Baseline in Endometrial Thickness After 4-cycle Treatment	Endometrial thickness was measured via transvaginal ultrasound examination. The endometrium is the inner membrane of the uterus. During the menstrual cycle, the endometrium grows to a thick, blood vessel-rich, glandular tissue layer.	From baseline to Cycle 4 (28 days per cycle)	No
Secondary	Number of Bleeding / Spotting Episodes	Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. An episode means a series of bleeding and/or spotting. The bleeding /spotting analyses are by intensity.	For the first 90 days	No
Secondary	Number of Bleeding / Spotting Days	Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. The bleeding /spotting analyses are by intensity.	For the first 90 days	No
Secondary	Participants With Withdrawal Bleeding	Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.	At Cycle 4 (28 days per cycle)	No
Secondary	Participants With Intracyclic Bleeding	Intracyclic bleedings were defined as bleedings while a participant takes active drugs.	At Cycle 4 (28 days per cycle)	No
Secondary	Participants With Non-heavy Intracyclic Bleeding	Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).	At Cycle 4 (28 days per cycle)	No
Secondary	Participants With Non-heavy Withdrawal Bleeding	Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).	At Cycle 4 (28 dyas per cycle)	No
Secondary	Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment	CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.	From baseline to Cycle 4 (28 days per cycle)	No
Secondary	Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment	CRP is a laboratory parameter giving an indication of inflammation, whose elevated levels that were defined by a lab suggest a potential inflammation.	From baseline to Cycle 4 (28 days per cycle)	No
Secondary	Change From Baseline in Serum Estradiol Level After 4-cycle Treatment	Estradiol is a predominant sex hormone that presents in female.	From baseline to Cycle 4 (28 days per cycle)	No
Secondary	Change From Baseline in Serum Progesterone Level at Cycle 4	Progesterone is a steroid hormone involving in the female menstrual cycle, pregnancy, etc.	From baseline to Cycle 4 (28 days per cycle)	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.